Oppenheimer Initiates Coverage On Clearside Biomedical with Outperform Rating, Announces Price Target of $5
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer has initiated coverage on Clearside Biomedical (NASDAQ:CLSD) with an Outperform rating and a price target of $5.
June 25, 2024 | 9:43 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has initiated coverage on Clearside Biomedical with an Outperform rating and a price target of $5, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating and a specific price target of $5 by a reputable analyst from Oppenheimer is likely to boost investor confidence and positively impact the stock price of Clearside Biomedical in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100